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Type II cGMP-dependent protein kinase (cGKII) iso-
lated from pig intestinal brush borders and type Ia cGK
(cGKI) purified from bovine lung were compared for
their ability to activate the cystic fibrosis transmem-
brane conductance regulator (CFTR)-Cl2 channel in ex-
cised, inside-out membrane patches from NIH-3T3 fibro-
blasts and from a rat intestinal cell line (IEC-CF7) stably
expressing recombinant CFTR. In both cell models, in
the presence of cGMP and ATP, cGKII was found to
mimic the effect of the catalytic subunit of cAMP-de-
pendent protein kinase (cAK) on opening CFTR-Cl2
channels, albeit with different kinetics (2–3-min lag
time, reduced rate of activation). By contrast, cGKI or a
monomeric cGKI catalytic fragment was incapable of
opening CFTR-Cl2 channels and also failed to potentiate
cGKII activation of the channels. The cAK activation but
not the cGKII activation was blocked by a cAK inhibitor
peptide. The slow activation by cGKII could not be
ascribed to counteracting protein phosphatases, since
neither calyculin A, a potent inhibitor of phosphatase 1
and 2A, nor ATPgS (adenosine 5*-O-(thiotriphosphate)),
producing stable thiophosphorylation, was able to en-
hance the activation kinetics. Channels preactivated by
cGKII closed instantaneously upon removal of ATP and
kinase but reopened in the presence of ATP alone. Par-
adoxically, immunoprecipitated CFTR or CF-2, a cloned
R domain fragment of CFTR (amino acids 645–835)
could be phosphorylated to a similar extent with only
minor kinetic differences by both isotypes of cGK. Phos-
phopeptide maps of CF-2 and CFTR, however, revealed
very subtle differences in site-specificity between the
cGK isoforms. These results indicate that cGKII, in con-
trast to cGKIa, is a potential activator of chloride trans-
port in CFTR-expressing cell types.
Guanosine 39,59-cyclic monophosphate (cGMP) has been
identified as an important intracellular mediator of salt and
water secretion in intestinal epithelium (1–3). Secretagogues
acting through the cGMP-signaling pathway include the family
of heat-stable enterotoxins (STs),1 low molecular weight pep-
tides secreted by enteropathogenic bacteria, and guanylin, a
recently discovered endogenous ST-like peptide hormone (3, 4).
Binding of ST or guanylin to the receptor domain of an intes-
tine-specific isoform of guanylyl cyclase (GC-C) triggers cyclase
activation, cGMP accumulation, and stimulation of net fluid
secretion through the activation of apical Cl2 channels in par-
allel with inhibition of coupled NaCl transporters (3, 5, 6). The
cystic fibrosis transmembrane conductance regulator (CFTR),
an epithelial Cl2 channel mutated in CF patients (7, 8), ap-
pears to be involved in the Cl2 secretory response to ST and
cGMP analogues, as evidenced by the absence of this response
in CF intestine (9, 10).
Several mechanisms have been proposed to link cGMP to the
CFTR-Cl2 channels, including (i) cGMP cross-activation of
cAMP-dependent protein kinase (11–13) followed by multisite-
phosphorylation of CFTR (14), (ii) direct interaction of cGMP
with the CFTR protein (15), and (iii) cGMP activation of an
intestine-specific isoform of cGMP-dependent protein kinase
(type II cGK; Refs. 16–19). cGKII was discovered as a cGMP-
sensitive 86-kDa phosphoprotein localized in intestinal brush
border membranes (16), which comigrated with a cGMP recep-
tor protein on one- and two-dimensional gels (17, 18). The
intestinal isoform is clearly distinct from the homodimeric type
Ia and Ib cGK (153–156 kDa) identified in other mammalian
tissues, as illustrated by differences in subcellular localization,
subunit composition, isoelectric point, phosphopeptide maps,
immunoreactivity, and affinity for cyclic nucleotide analogues
(17–19). Recently, molecular cloning of cGKII frommouse brain
(20) and rat intestine (21) demonstrated that cGKII is a differ-
ent gene product than cGKIa and Ib (22, 23).
In the present study, evidence for a functional difference
between cGK isoenzymes was obtained from studies of the
activation of CFTR-Cl2 channels in excised membrane patches
of an intestinal cell line (IEC-CF7; Ref. 24) or NIH-3T3 fibro-
blasts stably expressing recombinant CFTR (25). In both mod-
els, exposure of patches to a combination of cGMP and ATP
failed to elicit Cl2 channel activity. However, the further ad-
dition of purified cGKII, but not cGKIa, resulted in almost full
activation of CFTR-Cl2 currents.
Differential activation of the CFTR-Cl2 channel by cGKII is
the first example of isotype specificity in cGK regulation of
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cellular functions and provides a plausible explanation for the
prominent role of cGMP as a regulator of Cl2 transport in
intestinal epithelium in comparison to other CFTR-expressing
cell types in which cGKII expression is marginal or absent
(19–21).
EXPERIMENTAL PROCEDURES
Materials—Calyculin A was obtained from Calbiochem, San Diego,
CA. PKI, the Walsh inhibitor peptide (PKI(5–24)-amide) was obtained
from Dr. U. Walter, Wu¨rzburg, Germany. CF-2, a cloned R domain
peptide of CFTR (AA645–835), was produced in bacteria and purified as
described (26). Adenosine 59-triphosphate, sodium salt (ATP), and
cGMP were obtained from Boehringer Mannheim. [g-32P]ATP was ob-
tained from Amersham, UK. All other chemicals were from Sigma.
Cells and CFTR Expression Systems—Two cell types that stably
express CFTR were prepared and maintained as described previously
(24, 27). IEC-CF7 cells were obtained by stable transfection of the rat
fetal intestine-derived IEC-6 cell line with a plasmid encoding CFTR
(24); NIH-3T3 cells expressed CFTR after infection with a retroviral
vector encoding CFTR (27).
Isolation of Protein Kinases—cGKII was purified from the small
intestine of adult pigs (donated by the Department of Experimental
Cardiology, Erasmus University). The small intestine was dissected
from anesthetized pigs, rinsed with ice-cold 0.9% NaCl, and frozen in
liquid nitrogen. Brush border membrane vesicles were prepared from
the intestinal pieces by a freeze-thaw procedure and subsequent differ-
ential Mg21 precipitation and centrifugation as described previously
(28). cGKII extraction from the vesicles and purification by affinity
chromatography on 8-(2-aminoethyl)-amino-cAMP-Sepharose was per-
formed essentially as described (17, 18) with a slight modification. To
obtain detergent-free enzyme for use in the patch clamp experiments,
elution of cGKII from the affinity gel with 1 mM cGMP was performed
in the presence of 4 mM octyl glucoside rather than Triton X-100.
Subsequently, cGMP and octyl glucoside were removed by dialysis in
detergent-free patch clamp medium (see below).
The catalytic subunit of type II cAK and cGKI (characterized by
antibody analysis to be primarily the Ia isoform; Ref. 29) were purified
from bovine heart and bovine lung, respectively, as described (30, 31).
The specific activities (units/mg protein) of the purified protein kinases
as determined by the Kemptide phosphorylation assay (32) were 4.2
(cAK), 2.0 (cGKI), and 1.6 (cGKII), respectively. A monomeric constitu-
tively active cGKI fragment was obtained by limited trypsinization as
described (33).
Patch Clamp Technique—Patch clamp experiments were performed
as described by Hamill et al. (34). Glass (borosilicate) pipettes were
pulled to a resistance of 308 megohms and heat polished. Pipette
potential refers to the voltage applied to the pipette interior with
reference to the bath potential. Upward deflections denote negative
charge flowing out of the pipette. A List EPC-7 amplifier was used for
current amplification and voltage clamping. Membrane voltage was
continuously clamped at 240 mV, except when performing current-
voltage relationships. Data were monitored on an oscilloscope and
stored on a VCR. The recorded data were filtered at 50 or 100 Hz,
digitized at 200 Hz, and analyzed on a personal computer. Data anal-
ysis was performed as described by Kansen et al. (35). In view of the fact
that the high density of CFTR-Cl2 channels in membrane patches of the
3T3-CFTR fibroblasts hinders the accurate determination of open state
probability or number of channels, channel activity in these patches
was expressed in pA, rather than as the number of open channels. The
composition of the bath and pipette solutions was (in mM): 140 N-
methyl-D-glucamine, 1 EGTA, 3 MgCl2, and 10 Hepes-HCl (pH 7.3, final
Cl2 concentration 147 mM). In some experiments a low Cl2 pipette
buffer was used containing (in mM): 140 N-methyl-D-glucamine, 100
L-aspartic acid, 2 MgCl2, 5 CaCl2, and 10 Hepes-HCl (pH 7.3; final Cl
2
concentration 49 mM). Excised patches were studied in a solution ex-
change compartment (volume 1 ml), as described previously by Kansen
et al. (36). Experiments were performed at room temperature.
In Vitro Phosphorylation of CFTR and CF-2 and Phosphopeptide
Mapping—CFTR was immunoprecipitated from T84 cells using specific
CFTR antibodies and protein A-Sepharose beads as described (26).
CFTR attached to protein A-Sepharose beads (10 ml of suspension) or
CFTR antibody plus beads alone was incubated at 30 °C for 40 min in
100 ml of buffer containing 10 mMMgCl2, 1 mM EGTA, 10 mMHepes, pH
7.3, 50 mM MgATP, 20 mM cGMP, 10 Ci/mmol [g-32P]ATP, and purified
protein kinases (catalytic subunit of cAK, 2 milliunits/ml; cGKI, 7.5
milliunits/ml; cGKII, 9.4 milliunits/ml). The phosphorylated samples
were washed, resuspended in SDS-stop solution, and analyzed on 6%
SDS-PAGE as described previously (26). Phosphorylation conditions for
CF-2 (5 mM) were similar to those for CFTR. For kinetic experiments,
linear incorporation of 32P with time was ensured by (i) restricting the
incubation time to 5 min, (ii) varying the CF-2 concentrations between
0.1 and 0.5 mM, (iii) increasing the [g-32P]ATP concentration to 500 mM
(1 Ci/mmol), and (iv) using equal concentrations (25 nM) of each protein
kinase. Reactions were terminated by the addition of 20 ml of 70%
trichloroacetic acid, and protein pellets were washed three times with
0.2 ml of ice-cold H2O, suspended in 50 ml of SDS-stop buffer, boiled for
2 min, and subjected to 12% SDS-PAGE as described (26). 32P-Labeled
CF-2 or CFTR were excised from the dried gels, washed with two
changes of 10% acetic acid/30% methanol and three changes of 50%
methanol, and lyophilized. In the kinetic experiments, the incorpora-
tion of 32P into CF-2 was quantified by liquid scintillation spectrometry.
For two-dimensional phosphopeptide mapping of CF-2 and CFTR, 1 ml
of 50 mM NH4CO3, pH 8.0, containing L-1-tosylamido-2-phenylethyl
chloromethyl ketone-treated trypsin (50 mg/ml) was added to the dried
gel pieces and the mixture was incubated at 37 °C for 20 h (26). The gel
pieces were washed with 0.5 ml of 50 mMNH4HCO3 at 37 °C for 4 h, and
the collected supernatants were lyophilized. Phosphopeptides were sep-
arated on thin layer cellulose sheets (20 3 20 cm, Eastman Kodak Co.)
by electrophoresis in the first dimension, followed by chromatography
in the second dimension. Dried sheets were subjected to
autoradiography.
RESULTS
Activation of CFTR-Cl2 Channels by Protein Kinases—In
agreement with earlier studies of Cl2 channel activation in
excised, inside-out membrane patches from 3T3-CFTR fibro-
blasts (25, 37, 38), the addition of catalytic subunit of cAK (2
milliunits/ml) to the bath, in the presence of 2 mM MgATP,
resulted in rapid activation (lag time , 1 min) of multiple
anion-selective channels (average current increase per patch
40 6 38 pA at 240 mV holding potential; n 5 15) showing
characteristic properties of the CFTR-Cl2 channel (i.e. Cl2
selectivity, linear current-voltage relationship in symmetrical
Cl2 concentrations, 8 pS single channel conductance; results
not shown). A similar low conductance channel, occurring at a
much lower density (2–6 channels/patch) was activated by cAK
in excised patches from the rat intestinal IEC-CF7 cell line
stably expressing CFTR (24). In addition to cAK, the effect of
cGK on CFTR-Cl2 channel opening was examined in excised,
cell-free patches from both cell lines. Addition of MgATP (2 mM)
and cGMP (50 mM) together did not activate current in 3T3-
CFTR patches during 5–15 min observation (Fig. 1A). Inclusion
of the cGKI isoform purified from bovine lung (10 milliunits/ml)
likewise failed to open the CFTR-Cl2 channel (Fig. 1A), con-
firming earlier observations by Berger et al. (38). However, the
subsequent addition of saturating concentrations of the cGKII
(10 milliunits/ml) elicited a large Cl2 current, reaching a value
after 15 min that was 78 6 24% (n 5 5) of the maximal current
attained upon addition of saturating amounts of cAK (2 milli-
units/ml) to the same patch (Fig. 1A). Half-maximal cGKII-
activation (48 6 9% of the maximal cGKII response at 15 min;
n 5 5) was observed in the presence of 2 milliunits/ml cGKII,
whereas the threshold for current activation (10 6 6%; n 5 5)
was found at 0.5 milliunits/ml cGKII (data not shown). In
comparison to cAK, CFTR-Cl2 current activation by cGKII was
a relatively slow process (time required to reach half-maximal
activation following addition of 10 milliunits/ml cGKII: 8 6 1
min; for 2 milliunits/ml cAK: 0.7 6 0.2 min, n 5 6; Fig. 1, A and
B). This slow activation was unlikely to result from the activity
of counteracting protein phosphatases, since neither calyculin
A (1027 M), a potent inhibitor of phosphatase 1 and 2A (recently
implied in CFTR regulation; Refs. 38 and 39), nor the addi-
tional presence of ATPgS (1 mM) to produce stable thiophos-
phorylation, was able to enhance the CFTR activation kinetics
(results not shown).
The cGKII isoform, but not cGKI, was capable of activating
CFTR-Cl2 channels also in excised patches from IEC-CF7 cells
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(Fig. 2). In this low expression model, single-channel events
could be monitored (Fig. 2A), which had a linear I-V relation in
symmetrical Cl2 concentrations, a channel conductance of 8
pS, and a rightward shift in current reversal potential upon
lowering of the Cl2 concentration in the pipette (Fig. 2B). The
mean open probability (Po) of CFTR-Cl
2 channels measured at
the plateau phase of activation by saturating concentrations of
cGKII (0.22 6 0.09; n 5 9) did not differ significantly from the
Po of cAK-activated channels (0.23 6 0.12; n 5 8).
Additional proof of the identity of the cGKII-activated chan-
nel as CFTR came from the observation that cGKII could not
further enhance channel activity in excised patches from 3T3-
CFTR cells following their pre-phosphorylation by cAK (2 mil-
liunits/ml) and ATP (2 mM) (results not shown). Another simi-
larity between CFTR-Cl2 channel regulation by cAK and
cGKII was the observation that the currents rapidly returned
to near base-line values upon the removal of either kinase and
ATP from the bath, but could be restored almost instanta-
neously by the readdition of 2 mM ATP alone, confirming the
crucial role of ATP in CFTR-Cl2 channel functioning (Fig. 1B;
cf. Refs. 25, 38, and 40).
To eliminate the possibility that cGKII activation of CFTR
resulted from a contamination of the cGKII preparation with
cAK, a specific peptide inhibitor of cAK, PKI (0.1 mM) was added
to the bath. Under this condition CFTR-Cl2 channel activation
in 3T3 membrane patches by cAK (2 milliunits/ml) was com-
pletely abolished, whereas channel activation by cGKII (2 mil-
liunits/ml) was not significantly affected (42 6 3% of the max-
imal channel activity evoked by cAK in the same patch
following removal of PKI from the bath, as compared to 37 6
5% in the absence of PKI; n 5 5). Moreover, PKI was unable to
inhibit phosphorylation of Kemptide or CF-2 by cGKII (not
shown).
Finally, the possibility was considered that cGKI, in spite of
its failure to open CFTR-Cl2 channels by itself, could interfere
with the activation of CFTR-Cl2 channels by the other cGK
isoform. However, neither preincubation of 3T3 patches with
cGKI (10 milliunits/ml, 15 min; results not shown) nor the
simultaneous addition of cGKI (10 milliunits/ml) and cGKII (10
milliunits/ml) had any effect on the rate or extent of CFTR-Cl2
channel activation as compared to cGKII alone (Fig. 1C).
Phosphorylation of CFTR and CF-2 by cGK Isotypes—Phos-
phorylation studies carried out with CFTR immunoprecipitates
(Fig. 3A) and CF-2, the recombinant R domain of CFTR (Fig.
3B) confirmed previous reports that both proteins are excellent
in vitro substrates for cAK and cGKI (26, 38). This discrepancy
FIG. 1. cGKII but not cGKI activates CFTR-Cl2 channel cur-
rent in excised, inside-out membrane patches from 3T3-CFTR
fibroblasts. ATP (2 mM), cGMP (50 mM), cGKII (10 milliunits/ml), and
catalytic subunit of cAK (2 milliunits/ml) were present in the cytosolic
(bath) solution during the times indicated by the bars. Panel A, com-
parison of the effects of cGKI, cGKII, and cAK. The amount of current
activated by cGKII was 78 6 24% (n 5 5) of the current measured after
subsequent addition of cAK. Panel B, a representative example of an
experiment showing that the cGK-activated currents rapidly returned
to near base-line values upon removal of the kinase and ATP from the
bath (also shown for the cAK-activated currents in panel A), but could
be restored almost instantaneously by the readdition of ATP alone.
Panel C, time course of activation of CFTR-Cl2 current by cGKII alone
(l; 10 milliunits/ml) or a combination of cGKI (10 milliunits/ml) and
cGKII (); n 5 6. Current levels are expressed as a percentage of the
maximal CFTR-Cl2 current observed upon subsequent addition of 2
milliunits/ml cAK.
FIG. 2. Biophysical characteristics of the cGKII-activated
channel in excised, inside-out membrane patches from IEC-CF7
cells. Panel A, current tracings of cGKII-activated channels. Left, sym-
metrical 147/147 mM chloride solutions. Right, pipette buffer was re-
placed by a low (49 mM) chloride buffer. Tracings were obtained at the
indicated voltages. C, all channels closed; dotted line, single-channel
current levels. Panel B, I-V characteristics of the channel. The channel
conductance was 8.0 6 0.6 pS (n 5 5). l, symmetrical Cl2 solution
(147/147 mM); , reduction of Cl2 in the pipette to 49 mM by replace-
ment with aspartic acid.
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between phosphorylation and functional studies was even more
apparent from the kinetics of in vitro phosphorylation of CF-2
by cGKI and cGKII isoenzymes (Fig. 3B). CF-2 was a better
substrate for cGKI than for cGKII (similar Km; 3-fold higher
Vmax), and the plateau level of phosphate incorporation into
CFTR (Fig. 3A) was also higher for cGKI (140 6 11% of the
cGKII level; n 5 8).
Two-dimensional Phosphopeptide Mapping of CF-2 and
CFTR Phosphorylated by cAK, cGKI, and cGKII—Up to 10
serine residues within the R domain have been suggested to be
involved in the activation of CFTR (for review, see Ref. 39). In
order to investigate whether the isotype specificity of cGK
activation of the CFTR-Cl2 channel might be related to the
pattern of specific serine residues that are phosphorylated,
two-dimensional phosphopeptide mapping was performed of
CF-2 and CFTR phosphorylated by cAK, cGKI, and cGKII (Fig.
4). All three kinases phosphorylated the same peptides in CF-2
with very slight differences being observed in the intensities of
phosphorylation of individual peptides (Fig. 4, A–C). All three
kinases also phosphorylated the CFTR on a subset of the pep-
tides phosphorylated in CF-2 (Fig. 4, D–F), arguing against the
location of novel cGKII sites outside the R domain. Several
sites, in particular those located on peptides 1, 2, and 4 (the
latter containing serine 700; see Ref. 26), were phosphorylated
to a similar level. In contrast, one prominent peptide, labeled 9
(see Ref. 26 for numbering) was preferentially phosphorylated
by cAK and cGKII, but was phosphorylated to a much lower
level by cGKI (Fig. 4, D–F, and data not shown).
DISCUSSION
In this study a recently cloned cGK isoform, cGKII (20, 21),
expressed at high levels in the luminal membrane of intestinal
epithelial cells (16–19, 21, 41) and to a lower extent in kidney
and brain (21), is identified as a novel potential regulator of the
CFTR-Cl2 channel. Using a reconstitution assay consisting of a
detergent-free preparation of solubilized and purified cGKII,
inside-out membrane patches from CFTR-transfected intesti-
nal cells (IEC-CF7), or NIH-3T3 fibroblasts, Mg-ATP and
cGMP, the enzyme could almost fully mimic the effect of cAK
on CFTR-Cl2 channel opening, albeit with a slower time
course. It is possible, however, that the rate-limiting step in the
in vitro assay is the anchoring of the cGKII to the membrane,
and that this delayed opening does not necessarily imply a
similar kinetic disadvantage for cGKII in vivo, considering its
colocalization with CFTR in the luminal membrane (19, 41).
The amount of Cl2 channel current reached (78 6 24% of that
measured after the subsequent addition of cAK) was consider-
ably greater than the current level reported after addition of
another activating kinase, PKC, using similar assay conditions
(15 6 8% of cAK; Ref. 38). In accordance with these functional
data, the phosphopeptide maps made from CF-2 and CFTR
phosphorylated in vitro by cGKII and cAK were virtually iden-
FIG. 3. Phosphorylation of CFTR (panel A) and CF-2 (panel B) by purified protein kinases. Panel A, CFTR was immunoprecipitated
from T84 cells and phosphorylated as described under “Experimental Procedures.” The reactions also contained: catalytic subunit of cAK (2
milliunits/ml; lanes 1 and 2), cGKI (7.5 milliunits/ml; lanes 3 and 4), and cGKII (9.4 milliunits/ml; lanes 5 and 6). Lanes 2, 4, and 6, control
experiments in which CFTR was omitted. The 32P-labeled proteins were separated by 6% SDS-PAGE. The gel was dried and exposed to x-ray film.
CFTR migrates as a broad band of 180 kDa (“band C”; see Ref. 14). The 86- and 74-kDa bands represent residual amounts of autophosphorylated
cGKII (lanes 5 and 6, intact 86-kDa form 1 74-kDa proteolytic fragment; cf. Ref. 17) and cGKI (lanes 3 and 4, intact 74-kDa form), respectively,
remaining following the washing steps. Panel B, Lineweaver-Burk plots of CF-2 phosphorylation by equal concentrations (25 nM) of cAK, cGKI, and
cGKII. The experimental conditions needed to ensure linear rates of 32P incorporation are specified under “Experimental Procedures.” The inset
shows the kinetic constants (Km, Vmax) calculated from the Lineweaver-Burk plots. A.U., arbitrary units. Data represent the mean of three
experiments.
FIG. 4. Two-dimensional tryptic phosphopeptide maps of CF-2
and CFTR. Upper and lower panels, phosphopeptide maps of CF-2 and
CFTR, respectively, showing phosphorylation by cAK (A and D), cGKI
(B and E), and cGKII (C and F), respectively. Purified CF-2 and immu-
noprecipitated CFTR were phosphorylated for 40 min at 30 °C in the
presence of cAK (2 milliunits/ml), cGKI (7.5 milliunits/ml), or cGKII (9.4
milliunits/ml) as described under “Experimental Procedures.” The 32P-
labeled proteins were separated by 6% (CFTR) or 12% (CF-2) SDS-
PAGE and visualized by autoradiography. Radioactive bands of CF-2
(pooled middle and upper bands running at 30 and 32 kDa, respectively;
cf. Ref. 26) and CFTR (see Fig. 3A) were excised from gels, washed, and
digested for 20 h with 50 mg/ml L-1-tosylamido-2-phenylethyl chlorom-
ethyl ketone-treated trypsin. Tryptic digests were separated by electro-
phoresis in the first dimension at 400 V in 10% acetic acid, 1% pyridine,
pH 3.5, and by chromatography in the second dimension using pyridine:
1-butanol:water:acetic acid (10:15:12:3%). O, origin. Left, 1; right, 2.
Phosphopeptides are numbered from 1 to 9, and correspond to those in
Ref. 26. The results shown are representative of three independent
experiments. In two other sets of CF-2 maps, an additional phosphopep-
tide migrating closely to peptide 9 could be distinguished, indicating
that the peptide 9 spot may contain more than one peptide or more than
one phosphoacceptor site in one peptide, occasionally giving rise to
alternative tryptic digestion.
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tical and clearly different from the pattern generated by PKC
(26). The plateau level of phosphate incorporation into CFTR
reached with cAK and cGKII was also similar (Fig. 3A), al-
though the rate of CF-2 phosphorylation by cGKII was slower
(Fig. 3B). However, such a close correlation between in vitro
phosphorylation and functional data should be interpreted
with caution: cGKIa, another mammalian cGK isoform ex-
pressed in many non-intestinal cell types (30, 31) failed to
activate CFTR-Cl2 channels in this and an earlier study (38) or
to potentiate cGKII activation of the channel, in spite of its
ability to phosphorylate in vitro three of the four major cAK/
cGKII sites in CFTR (Fig. 4).
The molecular basis for the differential activation of the
CFTR-Cl2 channel by cGK isotypes is presently unclear. One
possibility is that cGKIa may not recognize one or more phos-
phoacceptor sites in CFTR that are crucial for its activation.
However, the results from the two-dimensional peptide map-
ping studies indicate that the pattern of phosphorylation of
CF-2 is similar for cGKI and cGKII and essentially the same as
that of cAK. Furthermore, the pattern of phosphorylation of
CFTR by the three kinases was also similar with the exception
that one peptide (peptide 9) was phosphorylated to only a very
low level by cGKI (Fig. 4). Although initial mutagenesis studies
suggested that the multisite phosphorylation of the R domain
is degenerate and that no single phosphorylation site is critical
for CFTR-Cl2 channel function (14), more recent studies pro-
vide evidence for a distinct role of subsets of phosphorylation
sites in controlling the function of the two nucleotide binding
domains in CFTR (39), and for the existence of stimulatory and
inhibitory phosphorylation sites in the R domain (42). How-
ever, the possible presence of a predominant inhibitory site
phosphorylated by cGKIa but not by cGKII or cAK seems
unlikely since CFTR-Cl2 channel activation by cGKII or cAK
was not inhibited by cGKI (Fig. 1C). A second possibility is that
the CFTR protein in its natural membrane environment is
differentially accessible to the cGK isoenzymes and that this
difference is lost following immunoprecipitation or in CF-2
peptide studies. Conceivably, differences in size or quaternary
structure between the monomeric cGKII protein (17–19) and
the cGKI dimer do not play a major role because limited
trypsinization of cGKIa generating a monomeric C-terminal
fragment failed to improve CFTR-Cl2 channel activation. On
the basis of secondary structure analysis, it has been argued
that the structural determinants accounting for the tight asso-
ciation of the type II cGK with membranes may reside in the
N-terminal region (21). Earlier topological studies in intestinal
brush borders have also pointed to a role of a 15-kDa N-
terminal fragment in anchoring cGKII to the microvillar cy-
toskeleton (17, 18). In particular the presence of a consensus
sequence for N-terminal myristoylation in cGKII (21) may have
functional significance. This sequence is absent in cGKIa (43),
which may explain in part its inability to activate CFTR. As a
third possibility, cGK activation of the CFTR-Cl2 channel may
depend on the additional phosphorylation of a CFTR-associated
regulatory protein ubiquitously expressed in cells of epithelial
origin (IEC-CF7) and non-epithelial cells (3T3 fibroblasts).
Small phosphorylatable proteins have been recently implicated
in the regulation of a different class of Cl2 channels (44, 45).
However, the opening of CFTR-Cl2 channels in lipid bilayers
by cAK does not require an auxiliary protein (46). Similar
studies performed with the cGK isotypes are clearly needed to
discriminate between a direct and indirect model of CFTR
regulation.
The demonstration of cGKII regulation of CFTR-Cl2 chan-
nels in membrane patches together with the high expression
level of cGKII and virtual absence of cGKI in intestinal epithe-
lium (17–19, 41) strongly support a model depicting cGKII as
the major effector of the action of cGMP and cGMP-linked
secretagogues (ST, guanylin) in this tissue. Recent immunolog-
ical and ion transport experiments (41) also show a tight cor-
relation between cGKII expression and 8-Br-cGMP-provoked,
but not 8-Br-cAMP-provoked Cl2 secretion in rat intestinal
segments and human colonic cell lines (T84, CaCo-2). With one
possible exception (47), the latter cell lines do not express
detectable levels of cGKII (41) but are still able to activate
CFTR in response to ST, apparently as a consequence of exces-
sive cGMP accumulation followed by cross-activation of cAK
(11–13). However, in a previous study no low affinity binding of
cGMP to cAMP receptors in the brush border membrane could
be detected following luminal exposure of rat small intestine to
ST in vivo (48). Moreover, in contrast to 8-Br-cAMP, ST did not
further enhance Cl2 secretion in rat small intestinal mucosa
and proximal colon in vitro beyond the level reached in the
presence of exogenous cGMP analogues (41). The apparent
need for coexpression of cGKII and CFTRmay also explain why
cGMP activation of Cl2 secretion is not universally observed in
other CFTR-expressing cell types, including human airway
epithelium (38).
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